Tag: Prescription Drugs

Displaying 121 - 140 of 162 results.

The Federal Trade Commission’s Bureau of Competition today issued a summary of agreements filed with the Commission in fiscal year 2005 (ending September 30, 2005) by generic and branded drug manufacturers. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 requires drug...
Commission approval of final consent order: Following a public comment period, the Commission has approved the issuance of a final consent order in the matter concerning Allergan, Inc.’s acquisition of Inamed Corporation. The vote to approve the final order was 4-0, with Commissioner J. Thomas...
The Federal Trade Commission today announced its intention to conduct a study of the use, and likely short- and long-term competitive effects, of authorized generics in the prescription drug marketplace. An authorized generic is chemically identical to a particular brand-name drug, but the brand-...
Botox marketer Allergan, Inc., and the Inamed Corporation will divest the rights to develop and distribute Reloxin, a potential Botox rival, to settle Federal Trade Commission charges that Allergan’s $3.2 billion purchase of Inamed would violate federal antitrust laws. The FTC alleges that...
Commission authorization of the filing of staff comment:The Commission has authorized the staffs of the Bureau of Consumer Protection, Bureau of Economics, and Office of Policy Planning to file a letter with the New Jersey Supreme Court Committee on Attorney Advertising regarding Proposed...
Under a consent agreement announced today, the Federal Trade Commission will allow Teva Pharmaceutical Industries Ltd.’s (Teva) proposed acquisition of IVAX Corporation (IVAX), provided the companies sell the rights and assets needed to manufacture and/or market 15 generic pharmaceutical products.
The Commission settled with Barr Laboratories concluding its federal court action challenging an agreement between Warner Chilcott and Barr in which, the Commission alleged, Barr agreed not to sell a lower-priced generic substitute of Warner Chilcott’s branded Ovcon 35, an oral...
The Federal Trade Commission today filed a complaint in federal district court seeking to put an end to an agreement between drug manufacturers Galen Chemicals Ltd. (now known as Warner Chilcott) and Barr Laboratories (Barr) that is denying consumers the choice of a lower-priced generic version of...
To resolve competitive concerns for three generic pharmaceuticals that arose from Novartis AG’s acquisition of Eon Labs, Inc., Novartis agreed to divest all the assets necessary to manufacture and market generic desipramine hydrochloride tablets, orphenadrine citrate extended release...
Preserving competition in U.S. markets for three generic pharmaceuticals, the Federal Trade Commission today approved Novartis AG’s (Novartis) $1.72 billion acquisition of Eon Labs, Inc. (Eon), provided Novartis divests three overlapping drugs to Amide Pharmaceutical, Inc. (Amide).
The Federal Trade Commission today filed a petition with the Court of Appeals for the Eleventh Circuit, in Atlanta, Georgia, requesting that the Court vacate its March 8, 2005 decision in the matter of FTC v. Schering-Plough Corporation, No. 04-10688, and re-hear the case en banc.
Commission response to Food and Drug Administration citizen petition: The Commission has authorized the submission of a response to the U.S. Food and Drug Administration (FDA) regarding a citizen petition filed with the FDA by IVAX Pharmaceuticals, Inc. (IVAX) on January 5, 2005. The petition...
Commission authorization of the staff to file amicus brief: The Commission has authorized the staff to file a brief as amicus curiae in Teva Pharmaceuticals USA, Inc. v. Pfizer, Inc., Case No. 04-1186 (Fed. Cir.) in support of Teva’s petition for rehearing or rehearing en banc. The case, which was...
Commission approval of final consent order: Following a public comment period, the Commission has approved a final consent order in the matter concerning Genzyme Corporation and ILEX Oncology, Inc. The Commission vote approving the final consent order was 4-0-1, with Commissioner Pamela Jones...
A consent order allowed Genzyme’s acquisition of ILEX Oncology, Inc., but requires the companies to divest certain assets in the market for solid organ transplant acute therapy drugs. Specifically, Genzyme is required to divest all contractual rights related to ILEX’s Campath®, an...
The Federal Trade Commission today announced that it will conditionally allow Genzyme Corporation’s (Genzyme) proposed $1 billion acquisition of ILEX Oncology, Inc. (Ilex), provided the companies divest overlapping assets in the U.S. market for solid organ transplant (SOT) acute therapy drugs....
Generic drug manufacturers Alpharma, Inc. and Perrigo Company will give up $6.25 million in illegal profits to settle Federal Trade Commission charges that their agreement to limit competition for over-the-counter (OTC) store-brand children’s liquid ibuprofen drove up prices and violated federal...
The consent order settled charges that Cephalon's proposed acquisition of Cima Labs, Inc. would allow Cephalon to continue its monopoly in the United States market for drugs that eliminate or reduce the spikes of severe pain that chronic cancer patients experience. The consent order...
The consent order settled antitrust concerns that Sanofi's proposed $64 billion acquisition of Aventis would create significant overlaps in several markets for pharmaceutical products while creating the world's third largest pharmaceutical company. Under terms of the consent order,...
By a 3-1-1 vote, the Federal Trade Commission today closed its investigation into Genzyme Corporation's (Genzyme) 2001 acquisition of Novazyme Pharmaceuticals, Inc. (Novazyme). At the time of its acquisition, Novazyme was engaged primarily in conducting early pre-clinical studies relating to...

Pages